Daewoong is projecting Nabota botulinum toxin sales of ₩300 billion this year, signaling aggressive volume push as it scales training for global distribution partners. The company is simultaneously defending against Medytox's tenfold damages claim in Korea—now ₩500 billion—over alleged strain contamination in Nabota batches.
Injectables
Daewoong Targets ₩300B Nabota Sales This Year
Korean toxin maker pushes volume as global training ramps and competitive pressure from Medytox intensifies.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Daewoong targets ₩300 billion Nabota sales this year amid legal fight with Medytox.
The revenue target is material. At ₩300 billion annually, Nabota is becoming a real revenue pillar for Daewoong outside Korea, where it competes directly against Botox and Dysport in markets where price and supply chain matter more than brand. The simultaneous legal exposure and expansion signal Daewoong is betting on volume and geographic diversification to weather the litigation and maintain market position.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.